Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer

Weisheng Zhang, Joe Zhu, Clay L. Efferson, Chris Ware, Jennifer Tammam, Minilik Angagaw, Jason Laskey, Kimberly A. Bettano, Shailaja Kasibhatla, John F. Reilly, Cyrille Sur, and Pradip K. Majumder

Departments of Imaging, Oncology, Pharmacology, and Laboratory Animal Research, Merck Research Laboratories, Boston, Massachusetts; and Imaging Department, Merck Research Laboratories, West Point, Pennsylvania

Abstract

Androgen receptors have been shown to play a critical role in prostate cancer. We used ultrasound imaging techniques to track tumor response to antiandrogen and rapamycin treatment in a prostate-specific Pten-deleted mouse model of cancer. Depletion of androgens by either surgical or chemical castration significantly inhibited tumor growth progression without altering the activation of Akt and mammalian target of rapamycin (mTOR). We also showed for the first time that targeting mTOR along with antiandrogen treatment exhibited additive antitumor effects in vivo when compared with single agents. Our preclinical data suggest that combination of antiandrogens with mTOR inhibitors might be more effective in treating androgen-dependent prostate cancer patients. [Cancer Res 2009;69(18):7466–72]

Introduction

The prevalence of prostate cancer is particularly high in developed countries and is the third most common cause of cancer-related deaths in men. Prevalence is now also increasing in developing nations (1). It was predicted by the American Cancer Society that in the United States alone, ~192,280 men would be diagnosed with prostate cancer and 27,360 deaths would be attributed to prostate cancer this year. Prostate cancer is the second most frequently diagnosed cancer in men in the United States with more than two million currently suffering from this disease. Although the death rate from prostate cancer is decreasing with the advent of early diagnosis, it still remains a leading cause of cancer-related death in men. Currently available treatment modalities include radical prostatectomy, chemotherapy, radiotherapy, and androgen ablation therapy.

The sex hormone testosterone plays a central role in the normal development and growth of male sex organs, as well as the abnormal growth of prostate cancer, through the androgen receptor (AR) signaling pathway (reviewed in ref. 2). Although the mechanism of androgen dependence in prostate tumor growth is not fully understood, the primary goal of treatment for prostate cancer in the clinic is to achieve suppression or inhibition of AR activation by androgen deprivation through surgical castration, estrogen, antiandrogens, or their combination (reviewed in ref. 3). Androgen ablation by either surgical castration or by luteinizing hormone–releasing hormone analogue strongly inhibits the growth of localized advanced cancer by eliminating circulating testosterone (4, 5). However, within only a few years after androgen ablation therapy, prostate cancer growth in these patients tends to become more aggressive as well as androgen-independent (reviewed in ref. 6). The mechanism of developed resistance to antiandrogens remains unclear, yet cell-based studies indicate that regulation of the phosphoinositide 3-kinase (PI3K) pathway by androgens may play a critical role in the development of androgen independent prostate cancer (7–9).

The PI3K pathway plays an important role in regulating several cellular functions including cell growth, proliferation, differentiation, and survival. Loss or functional alteration of the tumor suppressor gene PTEN activates downstream PI3K signaling, resulting in increased cell proliferation and survival (10–14). More than 20% of primary human prostate cancer is associated with deletion or functional loss of PTEN, whereas >50% of human metastatic prostate cancer specimens harbor biallelic loss of this gene, suggesting that PTEN might be responsible for the lethal form of the disease (15–24). Conventional deletion of both alleles of Pten leads to embryonic lethality (25, 26), whereas heterozygous Pten-null mice develop prostate intraepithelial neoplasia or PIN. These mice have been crossed with a number of other genetically engineered mice for further enhancement of the tumor phenotype [reviewed in Majumdar and colleagues (27)]. Loss of function mutations or lowered expression of PTEN increases the activity of important downstream targets of PI3K such as AKT in various cell lines and engineered mouse models (reviewed in refs. 28, 29). Activation of AKT1 in the prostate alone induces development of PIN but not invasive prostate cancer, whereas activation of AKT1 in a p27null null setting as well as prostate-specific deletion of Pten induces invasive cancer in mice (30–32). To understand the role of androgen ablation in the context of PI3K pathway activation, we have used a genetically engineered mouse model where PtenloxP/loxP mice (33) were crossed with ARR2-Pb-Cre transgenic mice (34). These mice spontaneously develop prostate tumors that recapitulate most human prostate cancer characteristics (32). However, selection and enrollment of these animals into a preclinical study are difficult due to the fact that the anatomic location of these tumors prohibits standard caliper measurements. Therefore, monitoring the kinetics of tumor response to a therapy in live animals is challenging. Here, we evaluated the use of the translatable three-dimension ultrasound
imaging technology to visualize and follow tumor development and response to androgen deprivation treatments. We show that this model is androgen dependent and that androgen blockade does not affect the activation of Akt or mammalian target of rapamycin (mTOR). We also show that simultaneous inhibition of mTOR and androgen signaling induces better antitumor effect in this model.

Materials and Methods

Animals. A conditional Pten-deficient model of prostate cancer (Pten\(^{loxP/loxP;Pb-Cre+}\)) in which Pten is homozygously deleted in the prostate gland due to prostate-specific expression of Cre recombinase (32) was used for these studies. This model was obtained from Dr. Hong Wu’s laboratory at the University of California in Los Angeles, CA. Both founder lines, the ARRP2Probasin-Cre (C+) transgenic mice (on C57BL/6xD2BA2 background; ref. 34) and the Pten\(^{loxP/loxP}\) mice (on a 129/BALB/c background), were maintained in our contract facility. The heterozygous Pten\(^{loxP/loxP;C/+}\) males were then bred to Pten\(^{loxP/loxP;C/+}\) females to obtain the Pten\(^{loxP/loxP;C/+}\) genotype. Male Pten\(^{loxP/loxP;C/+}\) mice between 14 and 76 wk of age were used for experiments. Mice were using an isolated barrier unit system on wood-chip bedding and fed standard rodent chow ad libitum. All animal procedures were reviewed and approved by the Merck Research Laboratories-Boston Institutional Animal Care and Use Committee.

3-Dimensional ultrasound imaging of prostate tumors. Mice were anesthetized with a continuous flow of 2% to 3% isoflurane in oxygen mixture (2.5 liters/min) in an induction chamber using the Vevo anesthesia system (VisualSonics, Inc.). Mice were placed on the Vevo Mouse Handling Table (37°C) in the Vevo Integrated Bair System (VisualSonics, Inc.) with continuous isoflurane anesthesia. Mouse fur was removed before ultrasound imaging. Ultrasound coupling gel AQUASONIC 100 (Parker Laboratories, Inc.) was applied directly to the skin. Mice were then scanned transversely from ventral body wall using the 710B real-time microvirtualization scanhead (probe) and Vevo770 High-resolution In vivo Micro-Imaging system (VisualSonics, Inc.). The 710B scanhead provides a center frequency at 20 MHz with 70 μm axial and 140 μm lateral resolution at the focal depth of 15 mm. The stepsize of scanning varies from 32 to 48 μm dependent on the scanning distance. The maximal field of view of the scanhead is 20.8 × 20.8 mm and the maximal scanning distance is 24 mm. Animals were scanned twice due to tumor growth in both anterior lobes of the prostate. A single scan was insufficient to cover both tumors in the same field of view. Three-dimensional images were reconstructed from two-dimensional section images using the Vevo770 system software following acquisition. Tumor volumes were determined using the three-dimensional Quantify Version 3.5 software (Robarts Research Institute).

Animal surgery and treatment. Animals were prescreened by ultrasound three-dimensional imaging to obtain a baseline tumor volume for enrollment and were randomized into groups based on tumor volumes. For studies using androgen ablation by surgical castration, 20 animals with tumors 324 to 739 mm\(^3\) were randomized into two groups. Ten animals were castrated by removal of both testicles following the standard operation procedure of Merck Institutional Animal Care and Use Committee protocols. The other 10 animals were kept as controls. Mice were imaged weekly. Nine weeks following castration, slow-releasing testosterone propionate pellets (100 mg of 90-day-releasing pellet purchased from Innovative Research of America) were implanted s.c. and ultrasound imaging resumed after a period of 2 wk. Testosterone pellets were then removed 5 wk following implantation and tumor kinetics were tracked for an additional 5 wk. Chemical castration studies were conducted with Casodex at the dose of 10 mg/kg, daily for 5 d a week (Monday to Friday). Tumor-bearing mice were also treated with Rapamycin (LC Laboratories) alone at the dose of 20 mg/kg, daily (Monday to Friday), or with the combination of Casodex + Rapamycin at their above indicated doses, daily (Monday to Friday) or by 0.5% methyl cellulose (as vehicle) for 8 wk. Mice were imaged weekly throughout treatment. BrdUrd (Roche) was administered ip. at a dose of 50 mg/kg. Mice were euthanized and tumors were dissected, weighed, and processed for further analysis at the conclusion of studies.

End point tumor assessment. Mice were euthanized using CO\(_2\) and entire tumors were collected and weighed. Due to the variable amount of fluid that the tumors in this model contain, net tumor weight was also measured after fluid removal. Animals were euthanized and tumor samples were collected when tumor volumes reached 10% of body weight or tumor size was out of range of the ultrasound transducer before study termination. Tumor samples were collected for histologic and biochemical analysis.

Plasma concentration of testosterone. Mice were euthanized using CO\(_2\) and 500 μL of blood was collected by cardiac puncture. Plasma was separated by centrifugation for 1 min at 12,000 × g and stored at −20°C for further analysis. Testosterone levels in plasma were determined by established ELISA per manufacture instruction (kit #KEG010; R&D Systems).

Histology and immunohistochemical analysis. Formalin-fixed paraffin-embedded tissues were sectioned at 5-μm thickness. Tissue sections were stained with H&E (Fisher) and analyzed for cell proliferation [BrdUrd, 1:500 (BD Bioscience); Ki-67, 1:500, Clone SP6 (Lab Vision)]. The status of phospho-S6 Ribosomal Protein (1:75; Cell Signaling Technology), PTEN (1:50; Cell Signaling Technology), phospho-AKT (S473; 1:50; Cell Signaling Technology), and AR (1:150; Lab Vision) were also measured. Automated staining was done using the ChromoMap kit on the Discovery XT (Ventana Medical System, Inc.) under standard conditions. Ki67 or BrdUrd-positive cells insides the ducts (not in the stromal compartment) of entire prostate sections were counted manually and number of positive cells/ducts was calculated.

Western blotting. Tumor samples were collected, flash frozen in liquid nitrogen, and stored at −80°C until processed. Frozen samples were thawed in cold radioimmunoprecipitation assay lysis buffer [0.5 mol/L Tris-HCl (pH 7.4), 1.5 mol/L NaCl, 2.5% deoxycholic acid, 10% NP40, 10 mmol/L EDTA; Upstate USA, Inc.] containing complete protease inhibitor cocktail (Roche Diagnostics Corporation). Or tumor samples were minced and subsequently homogenized with the Qiagen bead tissue lyser. Protein concentrations in cell and tissue lysates were determined by the Bicinchoninic Acid Protein Assay kit (Pierce Biotechnology) according to the manufacturer’s instructions. All proteins were detected by resolving proteins on Criterion 4-15% Tris-HCL SDS-PAGE (Bio-Rad Laboratories) and blotted onto nitrocellulose membrane. Residual binding sites were blocked by 5% nonfat dry milk and blotted with antibodies against phospho-AKT (S473; 1:1,000), phospho-S6R (1:1,000; Cell Signaling Technology, Inc.), Amyloid Precursor Protein (1:1,000; Cell Signaling Technology, Inc.), β-Actin (1:2,000; Abcam Inc.), and Tubulin (1:1,000; Abcam Inc.). Detection of protein bands was done using SuperSignal West Pico and Pentox Cholesterolin Substrate (Pierce Biotechnology) after incubation with the horseradish peroxidase–conjugated secondary antibody (1:5,000; Jackson Immuno Research Laboratories, Inc.).

Statistical analysis. A repeated measure ANOVA followed by Dunnett’s multiple comparison test was conducted to evaluate statistically significant differences of antitumor effects between groups.

Results

Detection of prostate tumors in Pten\(^{loxP/loxP;C/+}\) mice using noninvasive ultrasound imaging technology. For prostate tumor volume determination, we used both ultrasound and microcomputerized tomography imaging techniques (Supplementary Fig. S1). Fifty-five mice between 19 and 52 weeks of age were imaged with Ultrasound, and tumors were dissected and weighed. The smallest tumor was determined as 103 mm\(^3\). However, we have observed that this imaging technology can detect and measure much smaller tumors (data not shown). Tumor volumes measured by three-dimensional analysis of ultrasound images correlated well with the weights of fluid-containing tumors (R\(^2\) = 0.85; Supplementary Fig. S1). However, large tumors contained significant amounts of fluid and the volume of fluid varied markedly among tumors. Therefore, final tumor net weights showed less correlation with the ultrasound volumes at R\(^2\) = 0.65. H&E staining confirmed

www.aacrjournals.org 7467 Cancer Res 2009; 69: (18). September 15, 2009

Published Online First September 8, 2009; DOI: 10.1158/0008-5472.CAN-08-4385
that all tumors were late stage invasive adenocarcinomas (Supplementary Fig. S1). Additionally, we were able to detect the tumor in the same mice using microcomputerized tomography (Supplementary Fig. S1); however, it was difficult to quantify the tumor volume due to the poor contrast between tumor and surrounding genitourinary organs.

Analysis of 234 PtenloxP/loxP;C+C+ male mice between 20 and 76 weeks of age by ultrasound imaging showed that tumor development in this model is age dependent (Supplementary Fig. S2). All 233 animals eventually developed tumors with a minimum ultrasound volume of 12 mm³ to a maximum of 5,410 mm³ and one animal never developed tumor was confirmed to be misgenotyped. Tumor growth kinetics of 23 male mice over time was found to be heterogeneous (Supplementary Fig. S3). Rapidly growing tumors (16 of 23 mice) displayed doubling times of ~1.3 to 4.9 weeks, whereas slow growing tumors (5 of 23 mice) showed a 5.5 to 11.5 week doubling time. Two tumors seemed to be static with an extended doubling time of ~19 to 20 weeks.

Increased expression of phospho-Akt (S473) and phospho-S6RP in both early and late stages of tumor was associated with complete elimination of Pten expression in the luminal epithelial cells by both immunohistochemistry and Western analysis (data not shown; Supplementary Fig. S2), although other cell types remained Pten positive. Consistent with published report (32), these data suggest the PI3K pathway is activated in tumors irrespective of their age and size.

Prostate tumors in PtenloxP/loxP;C+C+ mice are sensitive to antiandrogens. Androgen ablation has been the most common approach for late stage prostate cancer treatment in the clinic. However, hormonal deprivation therapy only remains effective for ~2 to 3 years, after which tumors develop resistance and become hormone independent. To determine androgen dependency in the Pten-deficient tumor model, 44 Pten−/− deficient male mice between 22 and 52 weeks of age were prescanned for enrollment. Twenty mice with tumor volumes ranging from 324 to 739 mm³ (ages ranged from 26–46 weeks) were selected for the studies and were randomly assigned into two groups. One group was castrated by surgical removal of both testicles and the second group was assigned as controls (no surgical removal of testicles). Plasma testosterone level was measured and data showed an approximate 87% decrease upon

**Figure 1.** Pten-deficient tumors are sensitive to antiandrogens. A, tumor response to orchidectomy and testosterone replacement. Prostate tumors in Pten-deficient mice were imaged and the mice randomized into two groups (n = 10/group) based on tumor volume (~480 mm³). Mice in group 1 underwent bilateral castration and those in group 2 were kept as controls. Tumors were imaged and volume was measured weekly. Testosterone pellets were implanted 9 wk following castration. Testosterone pellets were removed at the end of week 15. Few mice as indicated by a, b, c, and d (2, 4, 1, and 1, respectively) were removed from the study due to large tumor size. Tumor volume data at the time of removal was included for the duration of the study in the data analysis. Tumor growth was significantly (P < 0.001) different at week 9 compared with week 1 in control mice, whereas no significant (NS) tumor growth progression was observed between week 1 and week 9 in castrated mice. However, significant (P < 0.05) tumor growth progression was observed when testosterone was administered in castrated mice at week 9. B, mice were enrolled into two groups (n = 10/group) as per their tumor volume (~840 mm³). Mice received either Casodex or 0.5% Methylcellulose (vehicle) and were imaged weekly. Percent change in tumor volume normalized to their baselines is depicted. Only mice that reached week 7 were included in the final data analysis. C, tumor weight was measured and compared with the final ultrasound measurement. *, **, and *** statistical significances at P < 0.05, P < 0.01, and P < 0.001 compared with the corresponding control mice.
Androgen ablation decreases tumor cell proliferation without affecting the activation of Akt or mTOR. Androgen ablation decreases tumor cell proliferation without affecting the activation of Akt or mTOR. Tumor-bearing mice were surgically castrated or treated Casodex for 9 wk. A, tumor sections from noncastrated (control) and surgically castrated mice were stained with H&E, antibody against AR, and Ki67. B, tumor sections from control, surgically castrated, and Casodex-treated were stained with antibodies against pAKT(S473) and pS6RP. Representative pictures of four mice per group. Scale bar, 50 μm.

To compare the effects of surgical castration to chemical castration in this model, we used the AR blocker Casodex to inhibit AR signaling. Animals with tumors ranging from 108 to 1,458 mm³ were enrolled and treated with either vehicle (n = 9) or Casodex (n = 10) at 10 mg/kg. Due to significant tumor volumetric variations, percent change of tumor volume was used to normalize tumor growth. Additionally, as a result of unexpected animal death (not related to the toxicity of Casodex) or tumor size out of range of detection (five each group) in first 3 weeks, only mice that reached week 7 were included in the final data analysis. Data showed that Casodex (n = 5) significantly inhibits tumor growth progression (only 4% increase compared with base level), whereas in the control (n = 4), tumor volume was increased 208% (compared with the base level) in 7 weeks (Fig. 1B). Mice were euthanized at the end of both studies (surgical castrations and chemical castration) and tumor weight was measured. Data showed a tumor net weight reduction along with a significant reduction in ultrasound measured volume following either surgical castration or Casodex treatment (Fig. 1C).

Activation of Akt/mTOR pathway remained unaffected by antiandrogens treatment. Androgen blockade significantly inhibited the progression of tumor growth in this model, but did not result in a complete tumor regression. To further explore tumor signaling pathways in this model, we focused on the PI3K/Akt/mTOR signaling pathway. Published data suggests that androgen-refractory status in androgen-dependent prostate cancer cells (37). In contrast, Hara and colleagues (38) suggested that activated Akt is not necessary for the invasiveness of androgen-refractory MDA-MB231 breast cancer cells. We analyzed tumors treated with either Casodex or surgical castration by H&E and immunohistochemistry. Here, we find that residual tumors have less AR-positive cells or lower level of nuclear AR in castrated mice compared with noncastrated controls (Fig. 2A). Furthermore, BrdUrd labeling and Ki-67 staining of these tumors suggested that these treated tumors were less proliferative (114.82 Ki67-positive cells/duct in noncastrated controls vs. 84.06 Ki67-positive cells/duct in castrated prostate; data not shown; Fig. 2A). However, no significant changes in caspase activation or terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling–positive cells were observed (data not shown). Adjacent tumor sections were also analyzed for changes in phospho-AKT (S473) and phospho-S6RP. Results revealed no change in the intensity of staining for either of these proteins, suggesting that both Akt and mTOR remain activated following androgen blockade by surgical castration (Fig. 2B). To test whether surgical and chemical castrations have different impact on the activation of Akt and mTOR, tumors treated with Casodex were stained with phospho-AKT (S473) and phospho-S6RP. Results indicated that Casodex also had no effect on the activation of Akt and mTOR in this model (Fig. 2B).

Combination of mTOR inhibitor and antiandrogen treatment shows additive antitumor efficacy. AR signaling and PI3K/Akt/mTOR pathways are active in a subset of human prostate cancer. Our data showed that AR and PI3K signaling pathways are
independently involved in tumor growth (Fig. 2), suggesting that simultaneously inhibition of both pathways may result in a better therapeutic response. Tumor-bearing mice were treated with either vehicle, Casodex, Rapamycin (an mTOR inhibitor), or a combination of Rapamycin and Casodex for a duration of 9 weeks. Tumors were measured once per week and tumor volumes were calculated. Significant antitumor effects of the combination group were seen as early as week 7, whereas tumor volumes of vehicle, Casodex, Rapamycin, and combination-treated mice were 1,154 + 112, 745 + 107, 637 + 128, and 417 + 129 mm³, respectively. At 9 weeks, tumor volumes were further reduced in the combination group (411 ± 138) compared with vehicle (1,366 ± 141), Casodex (805 ± 137), and Rapamycin (680 ± 136) groups. Data show a significant additive antitumor effect when mice were treated with the combination of Rapamycin and Casodex (Fig. 3A and B). Mice were euthanized and tumor weights were measured at the end of the study. Tumor weight data correlated with ultrasound measurements and display an additive effect when Rapamycin was combined with Casodex (Fig. 3C). Similarly, combination of surgical castration and mTOR inhibitor also reduced tumor burden compared with castrated tumors (Fig. 3D). Together, these data suggest additive antitumor efficacy is observed when antiandrogens are combined with mTOR inhibitor. To verify that the resulting efficacy was in response to the combination, we evaluated the effect of antiandrogens and mTOR inhibitors on their respective targets by immunohistochemical analysis of tumors collected 4 hours after the last dose of the efficacy study as shown in Fig. 3A. Casodex alone reduced nuclear AR levels or less AR-positive cells, whereas mTOR activity remains unaffected (Fig. 4, column 2). Rapamycin alone completely inhibited phosphorylation of S6RP, whereas AR was not affected (Fig. 4, column 3). Combination treatment with Casodex and Rapamycin inhibited both AR and phospho-S6RP levels (Fig. 4, column 4). BrdUrd staining showed that inhibition of tumor cell proliferation by either antiandrogen or mTOR inhibitor was further enhanced by the combination (Fig. 4, row 4). Together, these data show that inhibition of tumor cell proliferation by blocking both pathways enhanced therapeutic efficacy.

Discussion

Application of more clinically relevant preclinical cancer models will enhance the probability of success for identification, evaluation, and development of new drug candidates for the treatment of cancer patients. Noninvasive imaging technology enable accurate
Combinatorial Effect of mTOR Inhibitor and Antiandrogens

Figure 4. Inhibition of both AR and mTOR decrease tumor cell proliferation. Tumor-bearing mice were treated with vehicle (control), antiandrogen (Casodex), mTOR inhibitor (Rapa), and combination of Casodex and Rapamycin for 9 wk. Mice were euthanized and tumors were harvested 2 h after the last dose. Tumors were fixed, paraffin embedded, and sectioned. Five-micrometer-thick tumors sections were stained with H&E. Adjacent tumors sections were also stained with antibodies against phospho-S6RP (pS6RP), AR, or proliferation marker BrdUrd. Data represent six tumors in each treatment type. Scale bar, 50 μm for main images and 200 μm for insets.

quantification of tumor burden in vivo in real-time and facilitates the incorporation of genetically engineered mouse models in drug discovery programs. Ultrasound imaging technology was used to detect prostate tumors in the TGMAP mouse model (39, 40). However, these techniques have not been used in complex models that recapitulate human disease (such as Pten null mice). Here, we show that ultrasound measurements display significant correlations with actual tumor weights. We successfully show that high frequency ultrasound imaging provides a unique tool for sensitive detection of mouse prostate tumors that enables preclinical randomization based on tumor volumes and this is the first application of this imaging technique to monitor tumor progression and response to a therapy.

Tumor heterogeneity is crucial for progression, metastasis, and responsiveness to therapeutic modalities in the clinic and there are few animal models that can accurately mimic the nature of these tumors. With noninvasive imaging technologies, we have shown that following deletion of Pten, tumors in this model developed with heterogeneity and progression, which varied from tumor to tumor (Supplementary Figs. S2 and S3). Intratumor heterogeneity was also observed in this model by histologic analysis. For instance, the ratio of epithelial and stromal compartments in different sections of tumors varied and their rates of proliferation and activation of Akt or S6RP are heterogeneous, which resembles the human disease (data not shown; Supplementary Fig. S2; ref. 32).

It has been reported that early stage microscopic invasive adenocarcinoma can be detected at 16 weeks of age in the Pten null mouse model and they respond to castration with increasing apoptosis (32). However, residual invasive adenocarcinomas were still evident 2.5 months (10 weeks) after surgical castration (32). It has been suggested that Pten null prostate cancer cells can adapt to their new environment and become androgen independent (32). Our data suggest that tumors cells become less proliferative after androgen ablation compared with control but they remain sensitive to androgens (Figs. 1 and 2). When androgen was restored by implantation of testosterone pellets in the surgically castrated mice, the tumor growth progression resumed at a similar rate as the control animals (Fig. 1A). However, it is possible that 9 weeks of androgen ablation was insufficient to deplete the entire population of androgen dependent tumor cells and the remaining androgen-dependent tumor cells were still sensitive to testosterone (Fig. 1A).

The molecular mechanism underlying the initiation of androgen refractory prostate cancer is relatively unknown. PI3K/AKT/mTOR signaling pathways play a major role in the initiation and progression of these tumors in many preclinical mouse models, and cell-based data suggest that the PI3K/AKT/mTOR signaling network is also responsible for the development of androgen refractory tumors. However, this hypothesis has not been tested in any relevant preclinical models. Here, we show that Pten null prostate tumors are sensitive to antiandrogen treatment and remain androgen dependent without affecting the activation of Akt and mTOR (Fig. 2B). However, it might be possible for some tumors to escape after long-term treatment with antiandrogens in this model. These data suggest that the activation of the Akt or mTOR signaling network may not be the sole factor driving the development of an androgen refractory state when treated with antiandrogens.

Antiarrogens or complete androgen blockade and conventional chemotherapeutic approaches are effective in androgen-dependent prostate cancer (41). However, these agents do not result in complete tumor regression and clearance. Similarly, it has been shown that mTOR inhibitors reverse Pten/Akt/mTOR-mediated neoplasia and reduce tumor volumes in engineered mice (12, 13, 42). More recently, Kinkade and colleagues (43) and Carracedo and colleagues (44) reported that the combination of PI3K pathway inhibitor with extracellular signal-regulated kinase/mitogen-activated protein kinase signaling inhibitor might be more useful in preclinical models of hormone refractory prostate...
cancer. We have shown that combination of a PI3K pathway inhibitor with antiandrogen shows an additive benefit compared with any single agent alone in this mouse model of prostate cancer (Fig. 3). Our data indicate a rationale for combinational strategies of androgen blockade with either Akt and/or mTOR inhibition for further exploration in clinic.

In summary, high frequency ultrasound imaging is a very useful technique to randomize and monitor tumor growth progression of prostate cancer in the \( \text{Pten}^{\text{loxP/loxP}} \) model. Ultrasound as a method of tracking tumor progression enables a generalized application of these techniques in genetic mouse models for evaluation of preclinical drug candidates. The \( \text{Pten} \) null prostate tumor model resembles androgen-dependent prostate cancer in patients and responds to complete androgen blockade. In addition, activation of the Akt and mTOR pathway remained unchanged after chronic treatment with antiandrogens and combinations of antiandrogen and PI3K pathway inhibitor enhanced the efficacy of antiandrogens.

**Disclosure of Potential Conflicts of Interest**

All authors are or were employed by Merck & Co, Inc.

**Acknowledgments**

Received 11/17/08; revised 6/24/09; accepted 7/12/09; published OnlineFirst 9/8/09.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Nirah Shomer, Merck Research Laboratories–Boston, for providing animal resource support; Matthew III Walker for use of ultrasound imaging system; Christopher Tong and Shubing Wang, Merck Research Laboratories–West Point, for statistical analysis; and Katharine Elwood–Yen, Merck Research Laboratories–Boston, for her critical comments in this manuscript.

**References**


Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer

Weisheng Zhang, Joe Zhu, Clay L. Efferson, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-08-4385

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2009/08/24/0008-5472.CAN-08-4385.DC1

Cited articles
This article cites 44 articles, 19 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/18/7466.full.html#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
/content/69/18/7466.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.